Vetoquinol S.A. (0O1O.L) LSE
68.80
-1.7(-2.41%)
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
68.80
-1.7(-2.41%)
Currency In EUR
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2519
First IPO Date
March 05, 2013
| Name | Title | Pay | Year Born |
| Alain Masson | Deputy Chief Executive Officer & Pharmacist Manager | 202,310 | 1962 |
| Dominique Derveaux | Chief Operations Officer & Group Deputy Chief Executive Officer | 410,666 | 1969 |
| Matthieu Frechin | Chief Executive Officer & Non-Independent Chairman of the Board | 525,985 | 1969 |
| Sandrine Perrier | Chief Information Officer | 0 | N/A |
| Philippe Gruet | Chief Scientific Officer | 0 | N/A |
| Regis Vimal du Monteil | Chief Financial Officer | 0 | 1965 |
| Nathalie Arlecchini | Group Human Resources Director | 0 | N/A |
| Xavier Berthet | Director of Group Communications | 0 | N/A |
| Laurent Thore | Director of Partnerships, Legal Affairs & Risks | 0 | N/A |
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.